Home | WebMail | Register or Login

      Calgary | Regions | Local Traffic Report | Advertise on Action News | Contact

Health

World's 1st malaria vaccine to start pilot studies in Africa

Funding for phase one of pilot deployments of the world's first malaria vaccine in sub-Saharan Africa has been secured.

Vaccine is only partially effective and needs to be given in a four-dose schedule

A young girl with malaria rests in an inpatient ward in Malualkon, in the South Sudanese state of Northern Bahr el Ghazal, in 2012. The Global Fund to Fight AIDS, Tuberculosis and Malaria approved $15 million US for malaria vaccine pilots. (Adriane Ohanesian/Reuters)
Funding for phase one of pilotdeployments of the world's first malaria vaccine in sub-SaharanAfrica has been secured and immunization campaigns will begin in2018, the World Health Organization (WHO) says.

The vaccine, known as RTS,S or Mosquirix and developed byBritish drugmaker GlaxoSmithKline, is only partiallyeffective and needs to be given in a four-dose schedule, but isthe first approved shot against the mosquito-borne disease.

WHO said last year that while RTS,S was promising, itshould be deployed only on a pilot basis before any wide-scaleuse, given its limited efficacy.

Pedro Alonso, director of the WHO's Global Malariaprogram, said on Thursday that securing funding and being ableto trial the vaccine in Africa pilots would be a milestone inthe fight against malaria.

"These pilot projects will provide the evidence we need fromreal-life settings to make informed decisions on whether todeploy the vaccine on a wide scale," he said.

The go-ahead comes after the Global Fund to Fight AIDS,Tuberculosis and Malaria approved $15 million US forthe malaria vaccine pilots, assuring full funding for the firstphase of the program.

Earlier this year, the GAVI Vaccine Alliance and UNITAIDannounced commitments of up to $27.5 million and $9.6 millionrespectively for the first four years of the program.

Malaria infects around 200 million people a year worldwideand killed an estimated 440,000 in 2015. The vast majority ofmalaria deaths are among babies in sub-Saharan Africa.

RTS,S was developed by GSK in partnership with thenon-profit PATH Malaria Vaccine Initiative and part-funded bythe Bill & Melinda Gates Foundation.